贝莱特生物

最新新闻

• 评级变动
  Cantor Fitzgerald Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $270
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Tenax Therapeutics (TENX) and Belite Bio, Inc. ADR (BLTE)
  TipRanks · 2026/8/31
• Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $234
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $214
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• 评级变动
  Maxim Group Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $200
  \u5e02\u573a\u8d44\u8baf · 2026/8/16
• 评级变动
  Morgan Stanley Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $206
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $220
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Cantor Fitzgerald Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $266
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)
  TipRanks · 2026/9/9
• CCORF Initiates Belite Bio(BLTE.US) With Buy Rating, Announces Target Price $303
  \u5e02\u573a\u8d44\u8baf · 2026/9/4
• Belite Bio(BLTE.US) Officer Sells US$12.8 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE) and Daré Bioscience (DARE)
  TipRanks · 2026/8/16
• 评级变动
  H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $245
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  Mizuho Securities Remains a Buy on Belite Bio, Inc. ADR (BLTE)
  TipRanks · 2026/8/14
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Belite Bio, Inc. ADR (BLTE)
  TipRanks · 2026/8/15
• Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $220
  \u5e02\u573a\u8d44\u8baf · 2026/9/6
• 评级变动
  A Quick Look at Today's Ratings for Belite Bio(BLTE.US), With a Forecast Between $201 to $270
  \u5e02\u573a\u8d44\u8baf · 2026/8/15
• 评级变动
  BofA Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Announces Target Price $200
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• Belite Bio(BLTE.US) Officer Sells US$19.08 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 评级变动
  H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $245
  \u5e02\u573a\u8d44\u8baf · 2026/9/8

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。